| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10486415 | Value in Health | 2011 | 9 Pages |
Abstract
Linezolid and daptomycin are potentially cost-effective based on the assumptions of the DA model; however, linezolid appears to be more cost-effective compared to daptomycin and vancomycin for MRSA cSSSIs.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
Mark PharmD, Amir PharmD, Donald I. PharmD, David J. PhD,